niacinamide has been researched along with Diabetes Mellitus, Type 1 in 129 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this cohort of type 1 diabetes patients with mild-to-moderate CAN, a combination antioxidant treatment regimen did not prevent progression of CAN, had no beneficial effects on myocardial perfusion or DPN, and may have been detrimental." | 2.78 | Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. ( Brown, MB; Feldman, EL; Mehta, M; Plunkett, CD; Pop-Busui, R; Raffel, DM; Stevens, MJ; White, EA, 2013) |
| "At the dosage used, calcitriol has a modest effect on residual pancreatic beta-cell function and only temporarily reduces the insulin dose." | 2.72 | The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). ( Anguissola, GB; Bizzarri, C; Cavallo, MG; Crinò, A; Di Stasio, E; Guglielmi, C; Manfrini, S; Matteoli, MC; Patera, IP; Pitocco, D; Pozzilli, P; Spera, S; Suraci, C; Visalli, N, 2006) |
| "Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion." | 2.71 | European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. ( Bingley, PJ; Collier, T; Emmett, CL; Gale, EA, 2004) |
| "Recent onset type 1 diabetes patients (n=64, mean age 8." | 2.71 | A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). ( Beretta Anguissola, G; Bizzarri, C; Corbi, S; Crinò, A; Manca Bitti, ML; Manfrini, S; Matteoli, MC; Mesturino, C; Patera, IP; Pitocco, D; Pozzilli, P; Schiaffini, R; Spera, S; Suraci, C; Visalli, N, 2004) |
| "Individuals at high risk for developing IDDM within 3 years were identified by screening the siblings (age 3-12 years) of patients with IDDM for the presence of high titer (> or =20 Juvenile Diabetes Foundation [JDF] U) islet cell antibodies." | 2.69 | The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. ( Giani, G; Haastert, B; Heinze, E; Klinghammer, A; Kolb, H; Lampeter, EF; Scherbaum, WA, 1998) |
| "First degree relatives of type 1 diabetes children attending paediatric clinics in Norway were recruited." | 2.69 | [Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial]. ( Dahl-Jørgensen, K; Joner, G; Nicol-Smith, L; Rønningen, KS; Søvik, O; Torjesen, PA; Undlien, DE, 2000) |
| "For the first time, we studied 27 type 1 diabetes patients treated with NA for 12 months and then followed up for 1 year after discontinuance of NA." | 2.68 | Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. ( Baroni, MG; Boccuni, ML; Buzzetti, R; Cavallo, MG; Fioriti, E; Mesturino, C; Pozzilli, P; Signore, A; Valente, L; Visalli, N, 1995) |
| "Eighty-four IDDM patients between 5 and 35 years of age (mean age 15." | 2.68 | Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study) ( Amoretti, R; Baroni, MG; Buzzetti, R; Cavallo, MG; Crinò, A; De Mattia, G; Faldetta, MR; Fiori, R; Fioriti, E; Giovannini, C; Lucentini, L; Matteoli, MC; Mesturino, C; Multari, G; Paci, F; Pisano, L; Pozzilli, P; Romiti, A; Signore, A; Sulli, N; Suppa, M; Suraci, C; Suraci, MT; Teodonio, C; Visalli, N, 1997) |
| "These data suggest that treatment of Type 1 diabetes with nicotinamide at diagnosis is associated with a moderate increase of C-peptide secretion recovery." | 2.66 | Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. ( Casamitjana, R; Gomis, R; Mendola, G, 1989) |
| "Since type 1 diabetes is an immunologically mediated disease, immune intervention should alter the natural history of the disease." | 2.49 | Primary and secondary prevention of Type 1 diabetes. ( Skyler, JS, 2013) |
| "Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells." | 2.48 | Immunotherapies in diabetes mellitus type 1. ( Gupta, S, 2012) |
| "Prevention of type 1 diabetes in high risk individuals presents with both positive and negative aspects." | 2.42 | [Prevention of type 1 diabetes: what have we achieved? What should we say and propose next to families?]. ( Mattei, C; Nervi, S; Valéro, R; Vialettes, B, 2003) |
| " High-dose nicotinamide should still, however, be considered as a drug with toxic potential at adult doses in excess of 3 gm/day and unsupervised use should be discouraged." | 2.41 | Safety of high-dose nicotinamide: a review. ( Bingley, PJ; Douek, IF; Gale, EA; Gillmor, HA; Knip, M; McLean, AE; Moore, WP, 2000) |
| "In recent-onset type 1 diabetes, nicotinamide administration improves beta-cell function, without significantly decreased insulin requirements." | 2.40 | Nicotinamide in type 1 diabetes. Mechanism of action revisited. ( Burkart, V; Kolb, H, 1999) |
| "This ability to predict future cases of IDDM raises the possibility of intervention to prevent the disease." | 2.39 | Nicotinamide and diabetes prevention. ( Behme, MT, 1995) |
| "IDDM is caused by an immune-mediated destruction of the insulin-producing beta cells." | 2.39 | [Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group]. ( Andersen, HU; Pociot, F; Reimers, JI, 1994) |
| "Moreover, after the clinical onset of IDDM, most patients experience a transitory period of improved insulin secretion." | 2.38 | Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM? ( Eizirik, DL; Palmer, JP; Sandler, S, 1993) |
| "Type 1 diabetes is considered to be a chronic autoimmune disease characterized by gradual beta-cell destruction mediated by autoreactive T-lymphocytes during an asymptomatic prediabetic phase of varying duration." | 2.38 | [Can type-1 diabetes in children be prevented?]. ( Knip, M, 1992) |
| "The effects of Type 1 diabetes mellitus and of exposure to mainstream cigarette smoke on noradrenaline (NA) uptake and its subsequent metabolism by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) in the perfused lungs of rats were examined." | 1.28 | The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1. ( Bryan-Lluka, LJ; McKee, GJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (8.53) | 18.7374 |
| 1990's | 56 (43.41) | 18.2507 |
| 2000's | 48 (37.21) | 29.6817 |
| 2010's | 11 (8.53) | 24.3611 |
| 2020's | 3 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Faingold, MC | 1 |
| Luquez, C | 1 |
| Oviedo, A | 1 |
| Puchulu, F | 1 |
| Re, M | 1 |
| Torres-Méndez, JK | 1 |
| Niño-Narvión, J | 1 |
| Martinez-Santos, P | 1 |
| Diarte-Añazco, EMG | 1 |
| Méndez-Lara, KA | 1 |
| Del Olmo, TV | 1 |
| Rotllan, N | 1 |
| Julián, MT | 1 |
| Alonso, N | 1 |
| Mauricio, D | 1 |
| Camacho, M | 1 |
| Muñoz, JP | 1 |
| Rossell, J | 1 |
| Julve, J | 1 |
| Neyshaburinezhad, N | 1 |
| Seidabadi, M | 1 |
| Rouini, M | 1 |
| Lavasani, H | 1 |
| Foroumadi, A | 1 |
| Ardakani, YH | 1 |
| Kildegaard, J | 1 |
| Buckley, ST | 1 |
| Nielsen, RH | 1 |
| Povlsen, GK | 1 |
| Seested, T | 1 |
| Ribel, U | 1 |
| Olsen, HB | 1 |
| Ludvigsen, S | 1 |
| Jeppesen, CB | 1 |
| Refsgaard, HHF | 1 |
| Bendtsen, KM | 1 |
| Kristensen, NR | 1 |
| Hostrup, S | 1 |
| Sturis, J | 1 |
| Pop-Busui, R | 1 |
| Stevens, MJ | 1 |
| Raffel, DM | 1 |
| White, EA | 1 |
| Mehta, M | 1 |
| Plunkett, CD | 1 |
| Brown, MB | 1 |
| Feldman, EL | 1 |
| Fernandez, IC | 1 |
| Del Carmen Camberos, M | 1 |
| Passicot, GA | 1 |
| Martucci, LC | 1 |
| Cresto, JC | 1 |
| Arthur, JF | 1 |
| Shen, Y | 1 |
| Chen, Y | 1 |
| Qiao, J | 1 |
| Ni, R | 1 |
| Lu, Y | 1 |
| Andrews, RK | 1 |
| Gardiner, EE | 1 |
| Cheng, J | 1 |
| Simmons, K | 1 |
| Michels, AW | 1 |
| Furman, BL | 1 |
| Folwarczna, J | 1 |
| Janas, A | 1 |
| Pytlik, M | 1 |
| Cegieła, U | 1 |
| Śliwiński, L | 1 |
| Krivošíková, Z | 1 |
| Štefíková, K | 1 |
| Gajdoš, M | 1 |
| Skyler, JS | 4 |
| Jung, DY | 1 |
| Park, JB | 1 |
| Joo, SY | 1 |
| Joh, JW | 1 |
| Kwon, CH | 1 |
| Kwon, GY | 1 |
| Kim, SJ | 1 |
| Neshati, Z | 1 |
| Matin, MM | 1 |
| Bahrami, AR | 1 |
| Moghimi, A | 1 |
| Long, AE | 1 |
| Gooneratne, AT | 1 |
| Rokni, S | 1 |
| Williams, AJ | 1 |
| Bingley, PJ | 5 |
| Gupta, S | 1 |
| Kobayashi, T | 1 |
| Maruyama, T | 1 |
| Miyagawa, J | 2 |
| Hori, Y | 1 |
| Rulifson, IC | 1 |
| Tsai, BC | 1 |
| Heit, JJ | 1 |
| Cahoy, JD | 1 |
| Kim, SK | 1 |
| Philips, JC | 1 |
| Scheen, AJ | 1 |
| Couzin, J | 1 |
| Suarez-Pinzon, WL | 1 |
| Mabley, JG | 1 |
| Power, R | 1 |
| Szabó, C | 1 |
| Rabinovitch, A | 1 |
| ROGOZINSKI, R | 1 |
| Daaboul, J | 1 |
| Schatz, D | 1 |
| Vialettes, B | 3 |
| Valéro, R | 1 |
| Mattei, C | 1 |
| Nervi, S | 1 |
| Wang, PH | 1 |
| Gale, EA | 5 |
| Emmett, CL | 1 |
| Collier, T | 1 |
| Vendrame, F | 1 |
| Gottlieb, PA | 1 |
| Liu, HK | 1 |
| Green, BD | 1 |
| Flatt, PR | 1 |
| McClenaghan, NH | 1 |
| McCluskey, JT | 1 |
| Crinò, A | 4 |
| Schiaffini, R | 2 |
| Manfrini, S | 3 |
| Mesturino, C | 3 |
| Visalli, N | 8 |
| Beretta Anguissola, G | 1 |
| Suraci, C | 3 |
| Pitocco, D | 3 |
| Spera, S | 3 |
| Corbi, S | 1 |
| Matteoli, MC | 4 |
| Patera, IP | 2 |
| Manca Bitti, ML | 1 |
| Bizzarri, C | 2 |
| Pozzilli, P | 14 |
| Segev, H | 1 |
| Fishman, B | 1 |
| Ziskind, A | 1 |
| Shulman, M | 1 |
| Itskovitz-Eldor, J | 1 |
| Hyppönen, E | 1 |
| Kuntz, E | 1 |
| Pinget, M | 1 |
| Damgé, P | 1 |
| Karlsson Faresjö, MG | 1 |
| Ludvigsson, J | 2 |
| Reimers, JI | 4 |
| Larsen, CM | 1 |
| Mandrup-Poulsen, TR | 1 |
| Gosteli, J | 1 |
| Thomas, MC | 1 |
| Jerums, G | 1 |
| Tsalamandris, C | 1 |
| Macisaac, R | 1 |
| Panagiotopoulos, S | 1 |
| Cooper, ME | 1 |
| Ciampalini, P | 1 |
| Suraci, MC | 1 |
| Patera, P | 1 |
| Buzzetti, R | 5 |
| Guglielmi, C | 2 |
| Costanza, F | 1 |
| Fioriti, E | 4 |
| Olmos, PR | 1 |
| Hodgson, MI | 1 |
| Maiz, A | 1 |
| Manrique, M | 1 |
| De Valdés, MD | 1 |
| Foncea, R | 1 |
| Acosta, AM | 1 |
| Emmerich, MV | 1 |
| Velasco, S | 1 |
| Muñiz, OP | 1 |
| Oyarzún, CA | 1 |
| Claro, JC | 1 |
| Bastías, MJ | 1 |
| Toro, LA | 1 |
| Lo, HC | 1 |
| Tsai, FA | 1 |
| Wasser, SP | 1 |
| Yang, JG | 1 |
| Huang, BM | 1 |
| Hedman, M | 1 |
| Faresjö, MK | 1 |
| Kamal, M | 1 |
| Abbasy, AJ | 1 |
| Muslemani, AA | 1 |
| Bener, A | 1 |
| Ichii, H | 1 |
| Wang, X | 1 |
| Messinger, S | 1 |
| Alvarez, A | 1 |
| Fraker, C | 1 |
| Khan, A | 1 |
| Kuroda, Y | 1 |
| Inverardi, L | 1 |
| Goss, JA | 1 |
| Alejandro, R | 1 |
| Ricordi, C | 1 |
| Cabrera-Rode, E | 1 |
| Molina, G | 1 |
| Arranz, C | 1 |
| Vera, M | 1 |
| González, P | 1 |
| Suárez, R | 1 |
| Prieto, M | 1 |
| Padrón, S | 1 |
| León, R | 1 |
| Tillan, J | 1 |
| García, I | 1 |
| Tiberti, C | 1 |
| Rodríguez, OM | 1 |
| Gutiérrez, A | 1 |
| Fernández, T | 1 |
| Govea, A | 1 |
| Hernández, J | 1 |
| Chiong, D | 1 |
| Domínguez, E | 1 |
| Di Mario, U | 1 |
| Díaz-Díaz, O | 1 |
| Díaz-Horta, O | 1 |
| Di Stasio, E | 1 |
| Anguissola, GB | 1 |
| Cavallo, MG | 5 |
| Boucher, BJ | 1 |
| Chianelli, M | 1 |
| Parisella, MG | 1 |
| Mather, SJ | 1 |
| D'Alessandria, C | 1 |
| Signore, A | 5 |
| Mahon, JL | 1 |
| Sherr, J | 1 |
| Sosenko, J | 1 |
| Herold, KC | 1 |
| Eizirik, DL | 3 |
| Migliorini, RH | 1 |
| Rossini, AA | 1 |
| Mordes, JP | 1 |
| Gallina, DL | 1 |
| Like, AA | 1 |
| Baroni, MG | 4 |
| Boccuni, ML | 3 |
| Fava, D | 1 |
| Gragnoli, C | 1 |
| Andreani, D | 4 |
| Sandler, S | 2 |
| Welsh, N | 2 |
| Bendtzen, K | 1 |
| Hellerström, C | 2 |
| Eisenbarth, GS | 2 |
| Verge, CF | 1 |
| Allen, H | 1 |
| Rewers, MJ | 1 |
| Behme, MT | 1 |
| Valente, L | 1 |
| Kretowski, A | 3 |
| Kinalska, I | 3 |
| Kolb, H | 6 |
| Taboga, C | 1 |
| Tonutti, L | 1 |
| Noacco, C | 1 |
| Mandrup-Poulsen, T | 1 |
| Andersen, HU | 3 |
| Pociot, F | 3 |
| Karlsen, AE | 1 |
| Bjerre, U | 1 |
| Nerup, J | 2 |
| Lucentini, L | 2 |
| Kuntschen, F | 1 |
| Zumsteg, U | 1 |
| Elliott, RB | 4 |
| Pilcher, CC | 1 |
| Stewart, A | 1 |
| Fergusson, D | 1 |
| McGregor, MA | 1 |
| Alberti, KG | 1 |
| Haastert, B | 2 |
| Giani, G | 2 |
| Lampeter, EF | 2 |
| Palmer, JP | 3 |
| Reddy, S | 4 |
| Bibby, NJ | 2 |
| Wu, D | 1 |
| Swinney, C | 1 |
| Barrow, G | 1 |
| Margulis, B | 1 |
| Borg, LA | 1 |
| Wiklund, HJ | 1 |
| Saldeen, J | 1 |
| Flodström, M | 1 |
| Mello, MA | 1 |
| Andersson, A | 1 |
| Pipeleers, DG | 1 |
| Dedov, II | 1 |
| Gorelysheva, VA | 1 |
| Romanovskaia, GA | 1 |
| Filippov, IK | 1 |
| Smirnova, OM | 1 |
| Schernthaner, G | 1 |
| Greenbaum, CJ | 1 |
| Kahn, SE | 1 |
| Browne, PD | 1 |
| Schwertner, R | 1 |
| Rabl, W | 1 |
| Ziegler, AG | 1 |
| Spinas, GA | 1 |
| Hu, Y | 1 |
| Wang, Y | 1 |
| Wang, L | 1 |
| Zhang, H | 2 |
| Zhao, B | 1 |
| Zhang, A | 1 |
| Li, Y | 1 |
| Kim, JY | 1 |
| Chi, JK | 1 |
| Kim, EJ | 1 |
| Park, SY | 1 |
| Kim, YW | 1 |
| Lee, SK | 1 |
| Thivolet, C | 1 |
| Fiori, R | 1 |
| Romiti, A | 1 |
| Giovannini, C | 1 |
| Teodonio, C | 1 |
| Paci, F | 1 |
| Amoretti, R | 1 |
| Pisano, L | 1 |
| Multari, G | 1 |
| Suppa, M | 1 |
| Sulli, N | 1 |
| De Mattia, G | 1 |
| Faldetta, MR | 1 |
| Suraci, MT | 1 |
| Cunningham, JJ | 1 |
| Klinghammer, A | 1 |
| Scherbaum, WA | 1 |
| Heinze, E | 1 |
| Knip, M | 3 |
| Akerblom, HK | 1 |
| Weinand, S | 1 |
| Jahr, H | 1 |
| Hering, BJ | 1 |
| Federlin, K | 1 |
| Bretzel, RG | 1 |
| Burkart, V | 1 |
| Myśliwiec, J | 2 |
| Szelachowska, M | 2 |
| Kinalski, M | 2 |
| O'Brien, BA | 1 |
| Harmon, BV | 1 |
| Cameron, DP | 1 |
| Allan, DJ | 1 |
| Vidal, J | 1 |
| Fernández-Balsells, M | 1 |
| Sesmilo, G | 1 |
| Aguilera, E | 1 |
| Casamitjana, R | 2 |
| Gomis, R | 2 |
| Conget, I | 1 |
| Undlien, DE | 1 |
| Joner, G | 1 |
| Dahl-Jørgensen, K | 1 |
| Rønningen, KS | 1 |
| Nicol-Smith, L | 1 |
| Torjesen, PA | 1 |
| Søvik, O | 1 |
| Douek, IF | 1 |
| Moore, WP | 1 |
| Gillmor, HA | 1 |
| McLean, AE | 1 |
| Schatz, DA | 1 |
| Karanam, M | 1 |
| Robinson, E | 1 |
| Peck, AB | 1 |
| Cornelius, JG | 1 |
| Chaudhari, M | 1 |
| Shatz, D | 1 |
| Ramiya, VK | 1 |
| Young, M | 1 |
| Manna, R | 1 |
| Migliore, A | 1 |
| Martin, LS | 1 |
| Ferrara, E | 1 |
| Ponte, E | 1 |
| Marietti, G | 1 |
| Scuderi, F | 1 |
| Cristiano, G | 1 |
| Ghirlanda, G | 1 |
| Gambassi, G | 1 |
| Chase, P | 1 |
| Dupre, J | 1 |
| Mahon, J | 1 |
| Ehrlich, R | 1 |
| Gale, E | 1 |
| Lampeter, E | 1 |
| Kolb-Bachofen, V | 1 |
| Michalková, D | 1 |
| Kolár, J | 1 |
| Jancová, E | 1 |
| Barák, L | 1 |
| Sílesová, J | 1 |
| Lewis, CM | 1 |
| Canafax, DM | 1 |
| Sprafka, JM | 1 |
| Barbosa, JJ | 1 |
| Tanaka, Y | 1 |
| Kashiwagi, A | 1 |
| Shigeta, Y | 1 |
| McNally, PG | 1 |
| Feehally, J | 1 |
| Walls, J | 1 |
| Chase, HP | 2 |
| Bryan-Lluka, LJ | 1 |
| McKee, GJ | 1 |
| Butler-Simon, N | 1 |
| Garg, S | 1 |
| McDuffie, M | 1 |
| Hoops, SL | 1 |
| O'Brien, D | 1 |
| Mendola, G | 1 |
| Vague, P | 2 |
| Picq, R | 1 |
| Bernal, M | 1 |
| Lassmann-Vague, V | 2 |
| Herskowitz, RD | 1 |
| Jackson, RA | 1 |
| Soeldner, JS | 1 |
| Vallo, JJ | 1 |
| Nakajima, H | 1 |
| Yamada, K | 1 |
| Hanafusa, T | 1 |
| Fujino-Kurihara, H | 1 |
| Miyazaki, A | 1 |
| Saitoh, R | 1 |
| Minami, Y | 1 |
| Kono, N | 1 |
| Nonaka, K | 1 |
| Handfield-Jones, S | 2 |
| Jones, SK | 1 |
| Peachey, RD | 1 |
| Jones, S | 1 |
| Peachey, R | 1 |
| Obrosova, IG | 1 |
| Kirput', SN | 1 |
| Ostrovskiĭ, IuM | 1 |
| Larin, FS | 1 |
| Efimov, AS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial[NCT00116207] | Phase 3 | 44 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| TrialNet Pathway to Prevention of T1D[NCT00097292] | 75,000 participants (Anticipated) | Observational | 2004-02-29 | Recruiting | |||
| Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699] | Phase 3 | 176 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to Financial problem) | ||
| Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)[NCT01120119] | Phase 2 | 0 participants | Interventional | Completed | |||
| Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study[NCT00570102] | Phase 2 | 230 participants (Actual) | Interventional | 1995-02-28 | Completed | ||
| Three-Day Dosing NAD + Study[NCT03707652] | 8 participants (Actual) | Interventional | 2018-03-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
High Sensitivity CRP (nmol/L) (NCT00116207)
Timeframe: 24 months
| Intervention | nmol/L (Mean) |
|---|---|
| ORAL ANTIOXIDANT | 17.51 |
| Placebo | 16.95 |
ng of 8-epi prostaglandin F2alpha /G creatinine assessed in 24 hour urine collection (NCT00116207)
Timeframe: 24 months
| Intervention | ng/G creatinine (Mean) |
|---|---|
| ORAL ANTIOXIDANT | 2.92 |
| Placebo | 2.09 |
"Distal defects in [11C]meta-hydroxyephedrine ([11C]HED) retention involving at least 10 % of the left ventricle was used to define Cardiac Autonomic Neuropathy (CAN). The retention index (RI) is the unit of measure and is expressed as [11C]HEDblood min -1[ml tissue]-1~PET Data of Randomized Subjects at Baseline and 24-Months~The primary outcome was the change in the global [11C]HED RI = measure of cardiac innervation at 24 months in participants taking the active drug compared with those on placebo." (NCT00116207)
Timeframe: Baseline, 24 months
| Intervention | Retention index (Mean) | |
|---|---|---|
| BASELINE | 24 MONTHS | |
| ORAL ANTIOXIDANT | 0.081 | 0.070 |
| Placebo | 0.073 | 0.074 |
global myocardial blood flow reserve as a measure of endothelial function. Measured by PET using [13N]ammonia at rest and during adenosine stimulated coronary vasodilation. (NCT00116207)
Timeframe: Baseline, 24 months
| Intervention | ratio (rest:stress) (Mean) | |
|---|---|---|
| BASELINE | 24 MONTH | |
| ORAL ANTIOXIDANT | 2.95 | 3.02 |
| Placebo | 2.94 | 3.22 |
36 reviews available for niacinamide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus | 2014 |
Update on worldwide efforts to prevent type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Global Health; Humans; Models, Biological; Niacinamide; Randomized Contro | 2008 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine | 2012 |
Primary and secondary prevention of Type 1 diabetes.
Topics: Abatacept; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Autoantibodies; Child; Child, Presc | 2013 |
[Multicenter randomized trial on prevention of type 1 diabetes].
Topics: Autoantibodies; Biomarkers; Diabetes Mellitus, Type 1; Disease Progression; Glutamate Decarboxylase; | 2002 |
[Pharmacotherapies for type 1 diabetes mellitus].
Topics: Adjuvants, Immunologic; Animals; Biguanides; Chaperonin 60; Diabetes Mellitus, Type 1; Glycoside Hyd | 2002 |
[Regenerative medicine in diabetes by beta cell therapy and promotion of beta cell growth and differentiation].
Topics: Animals; Antigens, Neoplasm; Betacellulin; Biomarkers, Tumor; Cell Differentiation; Cell Division; D | 2002 |
Overview of prevention and intervention trials for type 1 diabetes.
Topics: Animals; Antibodies, Monoclonal; Antioxidants; Autoantigens; Clinical Trials as Topic; Cytokines; Di | 2003 |
[Prevention of type 1 diabetes: what have we achieved? What should we say and propose next to families?].
Topics: Autoantibodies; Biomarkers; Diabetes Mellitus, Type 1; Genetic Markers; Humans; Insulin; Niacinamide | 2003 |
Prediabetes: prediction and prevention trials.
Topics: Animals; Diabetes Mellitus, Type 1; Humans; Insulin; Niacinamide; Prediabetic State; Vitamin D | 2004 |
Micronutrients and the risk of type 1 diabetes: vitamin D, vitamin E, and nicotinamide.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Micronutrients; Niacinamide; Ris | 2004 |
Prediction and prevention of type 1 diabetes: progress, problems, and prospects.
Topics: Diabetes Mellitus, Type 1; Fatty Acids, Omega-3; Female; Forecasting; Humans; Hypoglycemic Agents; I | 2007 |
Prevention of type 1 diabetes: the time has come.
Topics: Autoantibodies; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Epitopes; Glucose Intolerance; | 2008 |
Nicotinamide and diabetes prevention.
Topics: Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; New Zealand; Niacinamide; Risk F | 1995 |
[Influence of nicotinamide on the course of insulin-dependent diabetes mellitus].
Topics: Diabetes Mellitus, Type 1; Humans; Niacinamide; Treatment Outcome | 1994 |
Immune intervention in type I diabetes mellitus--current clinical and experimental approaches.
Topics: Adjuvants, Immunologic; Cell Survival; Diabetes Mellitus, Type 1; Endocrinology; Humans; Immunosuppr | 1994 |
Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus.
Topics: Animals; Autoimmunity; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Free Radicals; Hu | 1993 |
[Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Islets of Langerhans; Niacinam | 1994 |
The potential role of nicotinamide in the secondary prevention of IDDM.
Topics: Diabetes Mellitus, Type 1; Humans; Nervous System Diseases; Niacinamide; Psychotic Disorders; Skin D | 1993 |
Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM?
Topics: Animals; Diabetes Mellitus, Type 1; Dietary Proteins; Glucose; Humans; Islets of Langerhans; Mice; M | 1993 |
Progress in the immunointervention of type-1 diabetes mellitus.
Topics: BCG Vaccine; Cyclosporine; Diabetes Mellitus, Type 1; Humans; Immunotherapy; Insulin; Niacinamide | 1995 |
Molecular mechanisms of beta-cell destruction in IDDM: the role of nicotinamide.
Topics: Diabetes Mellitus, Type 1; Humans; Islets of Langerhans; Niacinamide; Prediabetic State | 1996 |
Nicotinamide: potential for the prevention of type 1 diabetes?
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Europe; Humans; Islets of Langerhans | 1996 |
Prevention of insulin-dependent diabetes: where are we now?
Topics: Administration, Oral; Animals; Antigens; Diabetes Mellitus, Type 1; Finland; Humans; Immunosuppressi | 1996 |
Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists.
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus, Type 1; Humans; Insulin; Insulin Secretion; | 1996 |
[Insulin dependent diabetes (type I)--prophylaxis possibilities].
Topics: Diabetes Mellitus, Type 1; Early Intervention, Educational; Humans; Immunotherapy; Insulin; Niacinam | 1996 |
[Immunoprevention of Type I diabetes mellitus].
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Free Radical Scavengers; Histocompatibilit | 1996 |
[Pre-diabetes type 1. Evaluation of current clinical trials].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Insulin; Islets of Langerhans; Niacinam | 1997 |
Micronutrients as nutriceutical interventions in diabetes mellitus.
Topics: Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Micronutrients; Miner | 1998 |
Prevention of insulin-dependent diabetes mellitus 1998.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Niacinami | 1998 |
IDDM prevention trials in progress--a critical assessment.
Topics: Cell Death; Clinical Protocols; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Family; Feeding | 1998 |
Nicotinamide in type 1 diabetes. Mechanism of action revisited.
Topics: ADP Ribose Transferases; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Islets of Langer | 1999 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Safety of high-dose nicotinamide: a review.
Topics: Abnormalities, Drug-Induced; Adenoma, Islet Cell; Animals; Chemical and Drug Induced Liver Injury; D | 2000 |
Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Diabetes Mellitus, Type 1; Humans; Insulin; Mass Screening; Multicenter Studies as Topic; Niacinamid | 2001 |
Type 1 (insulin-dependent) diabetes mellitus and nitric oxide.
Topics: Animals; Cell Death; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Free Radicals; Huma | 1992 |
[Can type-1 diabetes in children be prevented?].
Topics: Child; Diabetes Mellitus, Type 1; Forecasting; Humans; Infant; Infant Food; Milk Proteins; Niacinami | 1992 |
32 trials available for niacinamide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allopurinol; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Neuropathies | 2013 |
[Info-congress. Study of the prevention of type 1 diabetes with nicotinamide: positive lessons of a negative clinical trial (ENDIT)].
Topics: Diabetes Mellitus, Type 1; Evidence-Based Medicine; Humans; Multicenter Studies as Topic; Niacinamid | 2002 |
Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Adolescent; Adult; Autoantibodies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind | 2003 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
Topics: Autoimmune Diseases; Diabetes Mellitus, Type 1; Disease Models, Animal; Double-Blind Method; Europe; | 2004 |
A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).
Topics: Adolescent; Aging; Antioxidants; C-Peptide; Child; Diabetes Mellitus, Type 1; Drug Therapy, Combinat | 2004 |
[European Nicotinamide Diabetes Intervention Trial (ENDIT)--secondary publication. A randomized, placebo-controlled trial of intervention before the onset of type 1 diabetes].
Topics: Adolescent; Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Niacina | 2005 |
Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diabetes Mellitus, Type 1; Glomerular Filtrati | 2005 |
A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus.
Topics: Adolescent; Adult; C-Peptide; Child; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female | 2005 |
Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics.
Topics: Adolescent; Adult; Autoantibodies; Child; Child, Preschool; Chile; Diabetes Mellitus, Type 1; Diabet | 2006 |
Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes.
Topics: Adolescent; Adult; Autoantigens; Child; Diabetes Mellitus, Type 1; Down-Regulation; Glutamate Decarb | 2006 |
Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes.
Topics: Adolescent; Adult; Autoantibodies; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 1 | 2006 |
The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).
Topics: Adolescent; Blood Glucose; Calcitriol; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; | 2006 |
Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Topics: Adolescent; Adult; Age Factors; Analysis of Variance; Blood Glucose; C-Peptide; Child; Child, Presch | 1995 |
Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Age of Onset; Child; Cyclosporine; Diabetes Mellitus, Ty | 1995 |
Residual B cell activity and insulin requirements in insulin-dependent diabetic patients treated from the beginning with high doses of nicotinamide. A two-year follow-up.
Topics: Adult; B-Lymphocytes; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Humans; Insulin; Male; N | 1994 |
Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; C-Peptide; Child; Child, Preschool; Diabet | 1994 |
On the sequential design of the Deutsche Nikotinamid Interventionsstudie--DENIS.
Topics: Child; Child, Preschool; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hypoglycemic Agents | 1993 |
Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nikotinamid Interventionsstudie-DENIS.
Topics: Autoantibodies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Follow-Up Studies; Germany; HLA- | 1993 |
Nicotinamide--biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992.
Topics: Animals; Denmark; Diabetes Mellitus, Type 1; Humans; Niacinamide; Poly(ADP-ribose) Polymerases; Pros | 1993 |
Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM.
Topics: Adult; Autoantibodies; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Family; Humans; Insulin | 1996 |
BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group.
Topics: Adolescent; BCG Vaccine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Follow-Up Studies; Gly | 1997 |
Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)
Topics: Adolescent; Adult; C-Peptide; Child; Child, Preschool; Diabetes Mellitus, Type 1; Glycated Hemoglobi | 1997 |
The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.
Topics: Austria; Autoantibodies; Biomarkers; Body Constitution; Body Mass Index; Child; Child, Preschool; Di | 1998 |
Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes.
Topics: Adult; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 1; Female; Glutamate Decarboxylase; Humans | 2000 |
[Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial].
Topics: Adult; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Genetic Markers; Genetic Predispositio | 2000 |
Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Diabetes Mellitus, Type 1; Humans; Insulin; Mass Screening; Multicenter Studies as Topic; Niacinamid | 2001 |
Double-blind randomized trial of nicotinamide on early-onset diabetes.
Topics: Blood Glucose Self-Monitoring; C-Peptide; Diabetes Mellitus, Type 1; Double-Blind Method; Glycated H | 1992 |
Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide.
Topics: Autoantibodies; Biomarkers; Child; Diabetes Mellitus, Type 1; Follow-Up Studies; Humans; Insulin; In | 1991 |
A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus.
Topics: Adolescent; C-Peptide; Child; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellit | 1990 |
Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.
Topics: Adolescent; Autoantibodies; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Female; | 1989 |
Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 1; Female; Glucagon; Glycated Hemoglobin; HLA-DR Antigens; | 1989 |
Nicotinamide may extend remission phase in insulin-dependent diabetes.
Topics: Administration, Oral; Adolescent; Adult; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; | 1987 |
62 other studies available for niacinamide and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)].
Topics: Aged; Blood Glucose; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypoglyc | 2022 |
Nicotinamide Prevents Diabetic Brain Inflammation via NAD+-Dependent Deacetylation Mechanisms.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Encephalitis; Male; Mice; Mice, | 2023 |
Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin.
Topics: Animals; Cytochrome P450 Family 2; Dextromethorphan; Diabetes Mellitus, Experimental; Diabetes Melli | 2020 |
Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Endothelial C | 2019 |
Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide - case reports.
Topics: Acetylcarnitine; Autoantibodies; Child; Child Development; Child, Preschool; Diabetes Mellitus, Type | 2013 |
Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of Type 1 diabetes.
Topics: Animals; Blood Platelets; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Femal | 2013 |
Streptozotocin-Induced Diabetic Models in Mice and Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet | 2015 |
Effects of Trigonelline, an Alkaloid Present in Coffee, on Diabetes-Induced Disorders in the Rat Skeletal System.
Topics: Alkaloids; Animals; Biomarkers; Bone Density; Coffea; Diabetes Complications; Diabetes Mellitus, Exp | 2016 |
Effect of nicotinamide on early graft failure following intraportal islet transplantation.
Topics: Animals; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 2009 |
Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats.
Topics: Alloxan; Animals; Cell Differentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; | 2010 |
The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort.
Topics: Adolescent; Adult; Autoantibodies; Cation Transport Proteins; Child; Cohort Studies; Diabetes Mellit | 2012 |
Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells.
Topics: Androstadienes; Animals; Biomarkers; Cell Aggregation; Cell Differentiation; Cell Line; Diabetes Mel | 2002 |
Niacinamide. Monograph.
Topics: Acute Disease; Animals; Anticonvulsants; Diabetes Mellitus, Type 1; Drug Interactions; Humans; Niaci | 2002 |
Clinical trials. Diabetes' brave new world.
Topics: Adolescent; Adult; Autoantibodies; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Disea | 2003 |
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
Topics: Aging; Animals; Apoptosis; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Interferon-gamma; Interleuk | 2003 |
[EFFECT OF SOME VITAMINS FROM THE B GROUP AND OF COCARBOXYLASE ON THE BLOOD SUGAR CURVE IN JUVENILE DIABETES MELLITUS].
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Folic Acid; Humans; Niacin; Niacinamide; Pharm | 1963 |
Growing pains in the pursuit of diabetes prevention.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Multicenter Studies as Topic; Niaci | 2004 |
Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells.
Topics: Animals; Butyrates; Cell Division; Cell Survival; Clone Cells; Diabetes Mellitus, Type 1; Glucose; I | 2004 |
Differentiation of human embryonic stem cells into insulin-producing clusters.
Topics: Apoptosis; Cell Culture Techniques; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 1 | 2004 |
Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats.
Topics: Animals; Blood Glucose; Cell Division; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; D | 2004 |
Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes.
Topics: Adolescent; Adult; Autoantigens; C-Reactive Protein; Child; Diabetes Mellitus, Type 1; Enzyme-Linked | 2005 |
Nicotinamide trials in diabetes intervention. Does a metabolite provide benefit?
Topics: Diabetes Mellitus, Type 1; Humans; Niacinamide; Placebos; Randomized Controlled Trials as Topic | 2005 |
Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz.:Fr. on glycemic responses in normal and diabetic rats.
Topics: Agaricales; Animals; Biomass; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dia | 2006 |
Effect of nicotinamide on newly diagnosed type 1 diabetic children.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug | 2006 |
Improved human islet isolation using nicotinamide.
Topics: Adenosine; Adult; Allopurinol; Cell Separation; Diabetes Mellitus, Type 1; Glutathione; Humans; Insu | 2006 |
The effects of calcitriol and nicotinamide on residual pancreatic beta-cell funtion in patients with recent-onset Type 1 diabetes (IMDIAB XI).
Topics: Calcitriol; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Niacinamide | 2007 |
Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Follow-Up Studies; Humans; Interleukin-2; Niaci | 2008 |
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT).
Topics: Adolescent; Autoimmunity; Child; Cohort Studies; Diabetes Mellitus, Type 1; Disease Progression; Eur | 2008 |
New trends in diabetes research: the search for an etiologically oriented treatment for type I diabetes mellitus.
Topics: Animals; B-Lymphocytes; Diabetes Mellitus, Type 1; Diet, Diabetic; Disease Models, Animal; Humans; I | 1983 |
Hormonal and environmental factors in the pathogenesis of BB rat diabetes.
Topics: 3-O-Methylglucose; Animals; Body Weight; Castration; Diabetes Mellitus, Experimental; Diabetes Melli | 1983 |
Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines.
Topics: Adult; Diabetes Mellitus, Type 1; DNA; Drug Interactions; Humans; Insulin; Insulin Secretion; Interf | 1994 |
The design of trials for prevention of IDDM.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Glucose Tolerance Test; Humans; Insulin; Niacin | 1993 |
[Current technologies and strategies in the treatment of insulin-dependent diabetes mellitus].
Topics: Administration, Intranasal; Diabetes Mellitus, Type 1; Humans; Injections, Jet; Insulin; Insulin Inf | 1994 |
The use of nicotinamide in the prevention of type 1 diabetes.
Topics: Animals; Child; Child, Preschool; Diabetes Mellitus, Type 1; Female; Humans; Mice; Mice, Inbred NOD; | 1993 |
Preventing insulin dependent diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Diet; Family; Humans; Niacinamide; Risk Factors | 1993 |
[Prevention of juvenile diabetes (type 1): reality or fiction?].
Topics: Adolescent; Autoimmunity; Child; Child, Preschool; Cyclosporine; Diabetes Mellitus, Type 1; Humans; | 1994 |
A combined casein-free-nicotinamide diet prevents diabetes in the NOD mouse with minimum insulitis.
Topics: Animals; Caseins; Diabetes Mellitus, Type 1; Diet, Protein-Restricted; Female; Fluorescent Antibody | 1995 |
Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus.
Topics: Adolescent; Adult; Aged; Animals; Antibody Specificity; Antioxidants; Apoptosis; Catalase; Child; Di | 1995 |
[Use of alpha-tocopherol acetate and nicotinamide at the onset of insulin dependent diabetes mellitus].
Topics: Adolescent; Adult; Antioxidants; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Islet | 1995 |
Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Free Radical Scavengers | 1996 |
Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age.
Topics: Age of Onset; Animals; Antioxidants; Diabetes Mellitus, Type 1; Female; Mice; Mice, Inbred NOD; Niac | 1997 |
IDDM preventive trials: what's new?
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diet; Humans; Insulin; Niacinamide; Nutritional | 1998 |
Oxygen radical production in human mononuclear blood cells is not suppressed by drugs used in clinical islet transplantation.
Topics: Diabetes Mellitus, Type 1; Humans; Immunosuppressive Agents; Interleukin-1; Islets of Langerhans Tra | 1999 |
Insulin increases in vitro production of Th2 profile cytokines in peripheral blood cultures in subjects at high risk of diabetes type 1 and patients with newly diagnosed IDDM.
Topics: Adolescent; Adult; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 1; Female; Humans; Insulin; I | 1999 |
Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-alpha in peripheral whole blood of people at high risk of developing type 1 diabetes and people with newly diagnosed type 1 diabetes.
Topics: Adult; Autoantibodies; Cells, Cultured; Diabetes Mellitus, Type 1; Family; Female; Humans; Insulin; | 2000 |
Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis.
Topics: Animals; Apoptosis; Cyclophosphamide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Is | 2000 |
Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.
Topics: Adoptive Transfer; Adult; Animals; Autoantibodies; Autoimmune Diseases; Cell Transplantation; Clinic | 2001 |
Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Diabetes Mellitus | 2001 |
Use of in vitro-generated, stem cell-derived islets to cure type 1 diabetes: how close are we?
Topics: Animals; Cell Culture Techniques; Cell Differentiation; Diabetes Mellitus, Type 1; Embryonic and Fet | 2002 |
IL-1beta expression in islet cells of the NOD mouse and its spatial relationship to beta cells and inducible nitric oxide synthase.
Topics: Animals; Cyclophosphamide; Diabetes Mellitus, Type 1; Enzyme Induction; Female; Gene Expression; Int | 2002 |
Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Humans; Insulin; Insulin Secretion; Islets of L | 1992 |
Nicotinamide and prevention of diabetes.
Topics: Diabetes Mellitus, Type 1; Family; Humans; Niacinamide | 1992 |
[Early intensification of treatment in diabetes using a combination of insulin and nicotinamide--effect on C-peptide levels and the course of the disease].
Topics: C-Peptide; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Insulin; Niacinamide | 1992 |
[Remission of diabetes mellitus].
Topics: Diabetes Mellitus, Type 1; Female; HLA Antigens; Humans; Immunosuppressive Agents; Insulin; Male; Ni | 1991 |
Diabetes, cyclosporin nephrotoxicity, and serum creatinine concentration.
Topics: Creatinine; Cyclosporins; Diabetes Mellitus, Type 1; Glomerular Filtration Rate; Humans; Kidney; Kid | 1991 |
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Topics: Animals; Biological Transport; Catechol O-Methyltransferase; Diabetes Mellitus, Experimental; Diabet | 1991 |
Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels.
Topics: Animals; Autoantibodies; Diabetes Mellitus, Type 1; Female; Islets of Langerhans; Male; Mice; Mice, | 1990 |
Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide.
Topics: Administration, Oral; Autoantibodies; Autoimmune Diseases; Diabetes Mellitus, Type 1; Drug Evaluatio | 1989 |
Elevated antibody-dependent cell-mediated cytotoxicity and its inhibition by nicotinamide in the diabetic NOD mouse.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1986 |
Nicotinamide treatment in diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Necrobiosis Lipoidica; Niacinamide | 1987 |
High dose nicotinamide in the treatment of necrobiosis lipoidica.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Drug Administration Schedule; Female; Humans; Male; Middle A | 1988 |
[The action of nicotinamide on the adenine nucleotide system as well as on mitochondrial oxidation and phosphorylation processes in the liver of db/db strain mice].
Topics: Adenine Nucleotides; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Mice; Mice, Inbred C57BL | 1988 |